BofA Gives Wave Life Sciences a Buy Rating, Eyes $38 Target
Bank of America starts coverage of Wave Life Sciences (WVE) with a Buy rating. Analyst highlights WVE-007 in obesity as a major growth driver, with peak sales above $11B.
/ 904 items
#Healthcare↓
Hims & Hers Launches $49 Wegovy Alternative, Shaking Up Weight Loss Market
Hims & Hers offers compounded semaglutide pill at $49/month introductory price, significantly undercutting Novo Nordisk's $199 Wegovy brand-name treatment with same active ingredient.
Guggenheim Starts Coverage on Stoke Therapeutics with Buy Rating and $60 Target
Guggenheim initiates coverage on Stoke Therapeutics, highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales.
Amgen Beats Q4 Expectations Despite FDA Drug Controversy
Amgen (AMGN) reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials.
Cumberland Pharma Gets FDA Fast Track for Groundbreaking DMD Heart Treatment
Cumberland Pharmaceuticals receives FDA Fast Track designation for ifetroban, a promising new oral therapy targeting fatal heart disease in Duchenne muscular dystrophy patients.
AbbVie Beats 2026 Profit Forecast Despite Market Concerns Over Drug Portfolio Mix
AbbVie (ABBV) reports strong Q4 earnings and raises 2026 profit outlook to $14.37-$14.57 per share, beating Wall Street estimates, though investors worry about Humira decline and aesthetics challenges.